Showing results (1291-1300 of 1,523) with videos related to

Sort By:
Pageof 153
Future Oncology (London, England)|December 17, 2021
INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistanceEgbert F Smit, Christophe Dooms, Jo Raskin, et al.
Lung Cancer (Amsterdam, Netherlands)|August 10, 2018
Factors associated with gene aberration test status and treatment decision in patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer: A multicenter survey in China (CTONG 1506)Yong Song, Qing Zhou, Xin Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 2, 2015
Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and ChemotherapyTony Mok, Yi-Long Wu, Jin Soo Lee, et al.
Stroke and Vascular Neurology|August 23, 2020
China Stroke Statistics 2019: A Report From the National Center for Healthcare Quality Management in Neurological Diseases, China National Clinical Research Center for Neurological Diseases, the Chinese Stroke Association, National Center for Chronic and Non-communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention and Institute for Global Neuroscience and Stroke CollaborationsYong-Jun Wang, Zi-Xiao Li, Hong-Qiu Gu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2022
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 StudyGilberto de Castro, Iveta Kudaba, Yi-Long Wu, et al.
BMC Cancer|February 26, 2016
Distribution and prognosis of uncommon metastases from non-small cell lung cancerFei-Yu Niu, Qing Zhou, Jin-Ji Yang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 12, 2017
Genetic and Immune Profiles of Solid Predominant Lung Adenocarcinoma Reveal Potential Immunotherapeutic StrategiesZhong-Yi Dong, Chao Zhang, Yu-Fa Li, et al.
Signal Transduction and Targeted Therapy|June 16, 2026
Neoadjuvant retlirafusp alfa (anti-PD-L1/TGF-β bifunctional fusion protein) with or without chemotherapy in unresectable stage III non-small cell lung cancer: updated results from the phase 2 TRAILBLAZER trialYi Pan, Xuening Yang, Qing Zhou, et al.
Frontiers in Neurology|May 3, 2021
Serum Phosphate and 1-Year Outcome in Patients With Acute Ischemic Stroke and Transient Ischemic AttackJun-Fang Zhang, Jing Jing, Xia Meng, et al.
Cancers|January 8, 2023
Longitudinal Plasma Proteomics-Derived Biomarkers Predict Response to MET Inhibitors for MET-Dysregulated NSCLCGuang-Ling Jie, Lun-Xi Peng, Mei-Mei Zheng, et al.
Pageof 153